Key features and details
- Purity: > 70% HPLC
- Suitable for: Blocking
Product nameMouse Lamin B1 peptide
Purity> 70 % HPLC.
70 - 90% by HPLC
Predicted molecular weight66 kDa
Our Abpromise guarantee covers the use of ab16375 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Blocking - Blocking peptide for Anti-Lamin B1 antibody - Nuclear Envelope Marker (ab16048)
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
- If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
- Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
- Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
- Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Information available upon request.
ReconstitutionReconstitute with 100 ul of deionised water (or equivalent).
- lamin B1
FunctionLamins are components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane, which is thought to provide a framework for the nuclear envelope and may also interact with chromatin.
Involvement in diseaseDefects in LMNB1 are the cause of leukodystrophy demyelinating autosomal dominant adult-onset (ADLD) [MIM:169500]. ADLD is a slowly progressive and fatal demyelinating leukodystrophy, presenting in the fourth or fifth decade of life. Clinically characterized by early autonomic abnormalities, pyramidal and cerebellar dysfunction, and symmetric demyelination of the CNS. It differs from multiple sclerosis and other demyelinating disorders in that neuropathology shows preservation of oligodendroglia in the presence of subtotal demyelination and lack of astrogliosis.
Sequence similaritiesBelongs to the intermediate filament family.
modificationsB-type lamins undergo a series of modifications, such as farnesylation and phosphorylation. Increased phosphorylation of the lamins occurs before envelope disintegration and probably plays a role in regulating lamin associations.
Cellular localizationNucleus inner membrane.
- Information by UniProt
All lanes : Anti-Lamin B1 antibody - Nuclear Envelope Marker (ab16048) at 1/1000 dilution
Lane 1 : HeLa whole cell lysate
Lane 2 : Hela whole cell lysate with
Mouse Lamin B1 peptide (ab16375) at 1 µg/ml
Lysates/proteins at 20 µg per lane.
All lanes : Alexa fluor goat polyclonal to Rabbit IgG at 1/10000 dilution
Performed under reducing conditions.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab16375 has been referenced in 1 publication.
- Roig MB et al. Identification of a novel cyclin required for the intrinsic apoptosis pathway in lymphoid cells. Cell Death Differ : (2008). PubMed: 18927588